Human immunode®ciency virus (HIV) RNase H activity is essential for the synthesis of viral DNA by HIV reverse transcriptase (HIV-RT). RNA cleavage by RNase H requires the presence of divalent metal ions, but the role of metal ions in the mechanism of RNA cleavage has not been resolved. We measured HIV RNase H activity associated with HIV-RT protein in the presence of different concentrations of either Mg 2+ , Mn 2+ , Co 2+ or a combination of these divalent metal ions. Polymerase-independent HIV RNase H was similar to or more active with Mn 2+ and Co 2+ compared with Mg 2+ . Activation of RNase H by these metal ions followed sigmoidal dose±response curves suggesting cooperative metal ion binding. Titration of Mg 2+ -bound HIV RNase H with Mn 2+ or Co 2+ ions generated bell-shaped activity dose± response curves. Higher activity could be achieved through simultaneous binding of more than one divalent metal ion at intermediate Mn 2+ and Co 2+ concentrations, and complete replacement of Mg 2+ occurred at higher Mn 2+ or Co 2+ concentrations. These results are consistent with a two-metal ion mechanism of RNA cleavage as previously suggested for a number of polymerase-associated nucleases. In contrast, the structurally highly homologous RNase HI from Escherichia coli is most strongly activated by Mg 2+ , is signi®cantly inhibited by submillimolar concentrations of Mn 2+ and most probably cleaves RNA via a one-metal ion mechanism. Based on this difference in active site structure, a series of small molecule N-hydroxyimides was identi®ed with signi®cant enzyme inhibitory potency and selectivity for HIV RNase H.
INTRODUCTION
Reverse transcription of human immunode®ciency virus (HIV) RNA is an essential early step in the virus life cycle following the entry of HIV into target cells. HIV reverse transcriptase protein (HIV-RT) requires the concerted function of two active sites to generate double-stranded DNA from the viral genomic RNA. The active HIV-RT protein is a heterodimer of a p66 and a p51 subunit. The p66 subunit contains a functional DNA polymerase and a separate RNase H active site. RNase H activity is required to hydrolyse the RNA strand of RNA:DNA heteroduplex molecules that are generated during reverse transcription. RNase H activity is also essential for the progression of two obligatory strand transfer reactions in the reverse transcription process (1, 2) .
Reverse transcription has been a highly successful antiretroviral target in HIV therapy in an effort to control the mortality and morbidity of HIV disease. Nucleoside analogues are chain terminators and inhibit DNA synthesis by HIV-RT after incorporation into nascent DNA molecules. Non-nucleoside inhibitors prevent DNA synthesis by HIV-RT after binding to an allosteric site on the polymerase domain of the p66 subunit. In combination, the use of HIV-RT inhibitors has provided treatment options with signi®cant ef®cacy and durability. However, there is still an urgent need to develop new antiviral agents and ®nd new targets due to the emergence of drug-resistant HIV strains and signi®cant cross-resistance within drug classes. Although RNase H was recognised as an essential viral function over a decade ago (3, 4) , very few inhibitors of RNA hydrolysis have been described and none of them has been progressed into clinical trials (5, 6) . Active site binding compounds have been shown to potently inhibit the polymerase-associated, divalent metal ion-dependent in¯u-enza RNA endonuclease in vitro and in vivo (7, 8) . Biochemical studies provided evidence that RNA hydrolysis by in¯uenza endonuclease occurred via a two-metal ion mechanism, similar to the model described for the exonuclease domain of Escherichia coli DNA polymerase I (9, 10) . Based on a pharmacophore model of inhibitor binding to a two-metal ion active site structure of in¯uenza endonuclease, we recently demonstrated that it was possible to design novel series of in¯uenza endonuclease inhibitors, which competitively bind to the endonuclease active site and do not inhibit divalent metal ion-dependent RNA polymerase activity (11) .
The role of divalent metal ions in the mechanism of RNA cleavage by HIV RNase H has remained unclear. Crystallographic analysis of the isolated HIV RNase H domain showed two Mn 2+ ions separated by~4 A Ê in the active site and bound to four conserved amino acids (D443, E478, D498 and D549), consistent with the two-metal ion mechanism model of RNA cleavage (12) . The measurement of metal ion binding to HIV-RT by solution calorimetry also suggested the binding of two Mn 2+ ions to the RNase H domain. However, at a concentration of 0.5 mM, only one Mg 2+ was found to bind (13) . Mg 2+ binding to the HIV RNase H domain has been shown to signi®cantly enhance DNA binding to HIV-RT. Three distinct binding modes were observed, which may correlate with DNA binding in the absence of Mg 2+ and binding to one and more than one Mg 2+ ion bound at increasing Mg 2+ concentrations (14) . Evidence for the binding of two Mg 2+ ions to HIV RNase H has also been obtained by solution NMR (15) .
On the other hand, the data available for the structurally very closely related E.coli RNase HI have been found to be more consistent with a one-metal ion mechanism of RNA cleavage (16, 17) . Crystallographic analysis showed a single Mg 2+ ion in the active site of E.coli RNase HI (18) . A single Mg 2+ -binding site was also observed for E.coli RNase HI using 1 H± 15 N heteronuclear NMR and con®rmed by kinetic analysis using 25 Mg-NMR (19, 20) . Two Mn 2+ ions were observed to bind to E.coli RNase HI by crystallography, at positions similar to those determined for HIV RNase H (21) . Escherichia coli RNase HI is signi®cantly more active in the presence of Mg 2+ compared with Mn 2+ , but RNA hydrolysis is measurable in the presence of Mn 2+ . In the presence of Mn 2+ , E.coli RNase HI shows highest activity at concentrations below 5 mM Mn 2+ , but is inhibited at concentrations above 5 mM Mn 2+ . Mn 2+ could also inhibit Mg 2+ -bound E.coli RNase HI activity. Based on these results, an activation/attenuation model has been suggested for E.coli RNase HI as an extension to the one-metal ion mechanistic model (22) .
The binding of divalent metal ions to RNase H has been shown to signi®cantly affect protein structure and stability (15, 23) . For the rational design of active site inhibitors of HIV RNase H, it is therefore of great importance to develop a better understanding of these structural effects and potential differences from closely related active site structures. In the current study, we further explored the effect of divalent metal ion binding on HIV-RT-associated RNase H activity. The titration of different divalent metal ions suggested cooperative binding to the enzyme and increased activity in mixed metal ion active sites, consistent with a two-metal ion mechanism of RNA cleavage. Activation of E.coli RNase HI was signi®cantly different, was inhibited by a low concentration of Mn 2+ and showed no evidence for cooperativity, in agreement with published results. Based on the previously developed pharmacophore of compound binding to two-metal ion active sites, we were able to identify a novel series of potent HIV RNase H inhibitors, which did not signi®cantly inhibit E.coli RNase HI.
MATERIALS AND METHODS

Materials
HIV-RT protein (p66/p51 dimer) was obtained from Amersham Bioscience or expressed and puri®ed using a previously described protocol, with modi®cations (24) . HXB2 p66 was co-expressed with HIV protease in E.coli, resulting in intracellular processing of p66 into p66/p51 dimers. Analytical ultracentrifugation showed that 86% of p66 was present in heterodimeric form (F.Mueller, personal communication). Cell paste was lysed in 20 mM Tris±HCl pH 8, 1 mM dithiothreitol (DTT), 1 mM EDTA, 100 mM NaCl, 20 mg/ml lysozyme by incubation for 15 min at 4°C and two 30 s sonications. Benzonase (5 U/ml; Novagen) was added and incubated for 15 min at 4°C. The lysate was centrifuged for 30 min using an SS34 Sorvall rotor at 17 000 r.p.m. and the supernatant passed through a Q Sepharose column equilibrated with buffer A (20 mM Tris±HCl pH 8, 1 mM DTT, 1 mM EDTA, 100 mM NaCl). The¯ow-through was collected and loaded onto a Hi Trap heparin±Sepharose column equilibrated in buffer B (20 mM Tris±HCl pH 8, 1 mM DTT, 1 mM EDTA, 50 mM NaCl). The bound protein was eluted with a 1.5 column volume gradient of buffer B to buffer B with 1 M NaCl. Fractions containing HIV-RT were pooled, and solid ammonium sulfate was added to a ®nal concentration of 1 M. The protein was then loaded onto a phenyl Sepharose column equilibrated in buffer C (20 mM Tris±HCl pH 8, 1 mM DTT, 1 mM EDTA, 1 M ammonium sulfate) and eluted with a 15 column volume gradient from buffer C to buffer B. Fractions containing HIV-RT protein were pooled, dialysed against buffer B, loaded onto a Resource S column equilibrated in buffer B and eluted in a 10 column volume gradient with buffer B with 1 M NaCl. Fractions containing HIV-RT protein were pooled, dialysed against buffer B and stored in aliquots at ±80°C. Escherichia coli RNase HI was obtained from Roche Applied Science.
Oligonucleotides were chemically synthesised and gel puri®ed after 5¢ labelling. Phosphate-labelled oligonucleotides were generated using T4 polynucleotide kinase from Roche Applied Science and [g-32 P]ATP from Amersham Bioscience. Cap-labelled RNA oligonucleotides were synthesised using a previously published procedure (25) . The oligonucleotidebased RNase H substrate GK1 was obtained by annealing 5¢-labelled RNA oligoucleotide R1 5¢-p*GAAUACUCAAG-CUAUGCAUC-3¢ with unlabelled DNA oligonucleotide D1 5¢-GATGCATAGCTTGAGTATTCTATAGTGAGTCGTA-TTAA-3¢. RNase H substrate CGK1 was obtained by annealing 5¢-cap-labelled R1 5¢-m7Gppp*GmAAUACUCAAGCUAUG-CAUC-3¢ with DNA oligonucleotide D1. Tritium-labelled RNase H substrate poly(dC:rG) was synthesised using T7 RNA polymerase and poly(dC) DNA from Amersham Bioscience. Poly(dC) (3.6 U/ml) was incubated with 40 mM [ 3 H]GTP (5 Ci / mmol) and 0.13 U/ml T7 RNA polymerase for 30 min at 37°C. The heteroduplex product was puri®ed by phenol extraction and ethanol precipitation, and unincorporated nucleotides were separated by G50 gel ®ltration.
Enzyme activity assays
In the standard gel-based HIV RNase assay, 0.1 nM substrate GK1 or CGK1, containing 5¢-labelled RNA (speci®c activity, 50 000±100 000 c.p.m./fmol), was incubated with 1 nM HIV-RT in buffer RH containing 50 mM Tris±HCl pH 7 or 8, 50 mM KCl, 1 mM MgCl 2 or 0.1 mM MnCl 2 and 0.1 mg/ml bovine serum albumin (BSA) in a total reaction volume of 5 ml for 0±10 min at 30°C. The reaction was stopped by the addition of 5 ml of denaturing gel loading buffer (Ambion). Reaction products were quanti®ed after electrophoresis on 7 M urea, 20% acrylamide gels by phosphorimager analysis (Storm, Amersham Bioscience), using Imagequant 5.2 software. Data analysis was performed using Excel 97 and SigmaPlot 5.0 software. The ®ltration-based RNase H assay combined 0.5 nM HIV-RT or 0.01 U/ml E.coli RNase HI with 0.1 mU/ml (OD 260 ) poly(dC:rG) substrate in buffer RH containing 10% dimethylsulfoxide (DMSO) in a total volume of 50 ml. After incubation at 37°C for 15 min, the reaction products were precipitated by adding 25 ml of cold trichloroacetic acid (TCA) and incubated at 4°C for 30 min before ®ltration through glass ®bre ®lters on Millipore NOB ®lterplates. The precipitates were washed ®ve times with 10% TCA and once with 70% ethanol, and quanti®ed by scintillation counting. For the analysis of RNase H inhibitor potencies, control reactions were included in the absence of inhibitor and corresponding activity was de®ned as 100% RNase H activity or 0% inhibition. Control reactions in the absence of protein were de®ned as 0% activity or 100% inhibition.
HIV-RT DNA polymerase activity was measured after incubating 1±4 nM HIV-RT protein, 5 mg/ml poly(rA) RNA, 2.5 mg/ml oligo(dT 16 ) DNA, 5 mM TTP, 0.15 mCi of [ 3 H]TTP in 50 mM Tris±HCl pH 8, 6 mM MgCl 2 , 50 mM NaCl, 1 mM EDTA, 10% DMSO at 37°C for 30 min. Product DNA was quanti®ed by TCA precipitation and scintillation counting as described above.
RESULTS
Cleavage pattern and metal ion preference of HIV RNase H
From structural and functional studies, the distance between the polymerase and RNase H active sites on HIV-RT has been determined as 18 bp on RNA:DNA heteroduplex substrates (26±30). On substrates longer than 18 bp, HIV RNase H preferentially cleaves at positions 18 and 8±9 nt from the 5¢ end of RNA on substrates containing 3¢-DNA overhangs. These cleavage reactions occur independently of each other with different rates, and the 18mer can serve as a substrate for the formation of the 9mer product (31, 32) . HIV RNase H generated the expected 18 and 9 nt major cleavage products from substrate GK1, which contains a 5¢-phosphorylated, 20 nt RNA hybridised to a 49 nt DNA oligonucleotide with a 3¢-DNA overhang (Fig. 1) . This preferred cleavage pattern was also observed when the RNA oligonucleotide was blocked at the 5¢ end by adding a guanosyl-5¢-5¢-guanosine triphosphate cap structure (substrate CGK1, Fig. 1 ). In agreement with previous observations, cleavage rates observed on capped and phosphorylated substrates were similar (33) . The formation of the 9mer cleavage product was signi®cantly slower than for the 18mer product and was strongly inhibited in the presence of 200 mM KCl (Fig. 1) . The formation of the primary 18mer product was more resistant to high salt, and the 18mer could also serve as a substrate for the formation of 9mer product (Fig. 1) . Escherichia coli RNase HI showed a signi®cantly different cleavage pattern on CGK1 substrate compared with HIV RNase H (Fig. 2) . Substrate CGK1 is therefore a useful probe for the differential analysis of HIV and E.coli RNase HI activities. Figure 2 shows that HIV RNase H activity was signi®cantly higher in the presence of Mn 2+ compared with Mg 2+ at pH 7. At pH 8, HIV RNase H activity was similar with Mg 2+ , Mn 2+ and Co 2+ (Fig. 3 ). Reduced activity with Mg 2+ at lower pH compared with Mn 2+ is consistent with a role for the catalytic metal ion in increasing the concentration of the nucleophile OH ± at the active site according to the respective pK a values of the metal hydrates (9) . On the other hand, E.coli RNase HI activity was low in the presence of Mn 2+ and highest in the presence of Mg 2+ (Fig. 2) . These results con®rmed the previously published preference of E.coli RNase HI for Mg 2+ and show a signi®cant difference in metal ion activation for the two structurally related enzymes.
Cooperative binding of divalent metal ions to activate HIV RNase H Previous evidence from structural studies indicated that HIV RNase H can accommodate two divalent metal ions in the active site. Using substrate CGK1, the rates of formation of the HIV-speci®c 9mer cleavage product were determined at different concentrations of either Mg 2+ , Mn 2+ or Co 2+ as activating divalent metal ions. About 10-fold higher concentrations of Mg 2+ were required to achieve maximal cleavage rates compared with Mn 2+ or Co 2+ . Maximal cleavage rates were similar for the three metal ions at pH 8 (Fig. 3) . Interestingly, dose±response curves of metal ion titration experiments showed slopes greater than unity, and Hill plots of the dose±response curves consistently showed Hill coef®cients larger than 1 for the activation of HIV RNase H (Fig. 3c±f) . These results suggested cooperative binding of more than one divalent metal ion to activate the generation of 9mer product from substrate CGK1 by HIV-RT.
One important implication of a two-metal ion mechanism of RNA cleavage is that stepwise titration should occur when a pre-bound divalent metal ion (M1±M1) is exchanged with increasing concentrations of a second type of divalent metal ion (M2) to form ®rst a mixed active site (M1±M2), followed by a homogeneous two-metal ion active site (M2±M2) at higher concentrations of M2. It has previously been observed with in¯uenza RNA endonuclease and the hammerhead ribozyme RNA hydrolysis activities that mixed M1±M2 active sites could have higher activities than homogeneous M1±M1 sites under certain conditions (9, 34) . Stepwise titration of metal ions will lead to bell-shaped titration curves under these conditions. HIV RNase H also showed more than an additive increase in RNA cleavage activity when low concentrations of either Mn 2+ or Co 2+ were combined with Mg 2+ -bound HIV-RT (Fig. 3a and b) . Titration of Mg 2+ -bound HIV-RT with either Mn 2+ or Co 2+ generated bell-shaped titration curves (Fig. 3c and d (Fig. 3c and d) , indicating complete replacement of Mg 2+ at these higher concentrations.
Inhibition of HIV RNAse H by N-hydroxyimides
The results described above were most consistent with a twometal ion mechanism for the formation of 9mer product from substrate CGK1 by HIV RNase H, but were dif®cult to reconcile with a one-metal ion or activation/attenuation mechanism. We have previously developed a pharmacophore model for the binding of compounds to the two-metal ion active site of in¯uenza endonuclease. The major feature of the pharmacophore is a speci®c arrangement of three oxygen atoms to mimic the metal ion-mediated protein interaction with substrate, nucleophile and leaving group oxygens in the enzyme active site (11) . In this model, the catalytic divalent metal ions are bound at a distance of 4±5 A Ê in the active site, and each metal ion interacts with two out of three compound oxygen atoms at 2±2.5 A Ê distance (Fig. 4a) . Compound 1 is a prototype structure to present the oxygen atoms for optimal metal ion interaction with two metal ions bound at 4±5 A Ê distance (Fig. 4) . As predicted, compound 1 inhibited the generation of 9mer product from substrate CGK1 (Fig. 4c and  d) . Complete inhibition was observed at 10 mM, with an IC 50 of 0.6 mM (Table 1) . Similarly, in a ®ltration assay format, using poly(dC:rG) as a template, compound 1 inhibited HIV RNase H activity with an IC 50 of 1 mM (Fig. 4e) . Under the same conditions, compound 1 did not show signi®cant inhibition of E.coli RNase HI activity (Fig. 4e, Table 1 ). Inhibition of HIV-RT DNA polymerase activity was detectable with an IC 50 of 40 mM. Compounds 2±8 were used to characterise structural features of HIV RNase H inhibition by this class of compounds (Fig. 4b) . In particular, the requirement for the oxygen ligands for inhibitory potency was investigated. The N-hydroxyl group, which represents the bridging ligand for both metal ions, was found to be essential. RNase H inhibitory potency was lost when the hydroxyl group was replaced by a methoxy or an amino group (compounds 3 and 4). Substitutions on the phenyl moiety could further modulate inhibitory potency and selectivity in this series (compounds 7 and 8).
DISCUSSION
Metal ion binding to the active site of HIV RNase H is a critical factor to consider in the design of inhibitors targeting this essential viral function. In particular, a one-metal or a two-metal ion active site will provide signi®cantly different binding environments for small molecules. As shown before, cross-titration of divalent metal ions with different physicochemical properties can generate characteristic bell-shaped titration curves, due to the fact that mixed metal active sites can have higher activities. In contrast, one-metal ion active sites will show typical hyperbolic titration curves due to single metal ion exchange in the active site (9,34).
The assay system described here to measure HIV RNase H activity is based on substrate GK1, a 20mer RNA hybridized to a 49mer DNA with a 3¢-DNA overhang. The length of this substrate is expected to span the nucleic acid-binding site on HIV-RT from the polymerase to the RNase H active site (26) . As demonstrated before, this nucleic acid structure will direct binding of the polymerase domain of HIV-RT to the RNA 5¢ end, leading to a preferential fast primary cleavage site 18 nt downstream of the RNA 5¢ end and a preferential slow secondary cleavage site 9 nt downstream of the RNA 5¢ end (31, 32) . The 9mer formation occurs independently of the 18mer formation and constitutes an essential polymeraseindependent RNA cleavage activity that is easily monitored in time course measurements. It is not known if HIV-RT undergoes a conformational change to perform 18mer and 9mer cleavages, or if a rigid HIV-RT protein slides along the substrate to cleave the RNA. A hinge region involved in a conformational change during this process may constitute a potential new drug-binding site. If HIV-RT went through a simple, rigid sliding motion along substrate GK1, then the polymerase active site would have to release the doublestranded nucleic acid interaction in order for RNA cleavage to occur at the 9mer site. This should be associated with a lower af®nity substrate interaction leading to higher sensitivity to high salt conditions. Interestingly, RNA cleavage rates decreased with increasing ionic strength of the reaction. In particular, there was no 9mer cleavage product detectable when the reaction was performed in the presence of 200 mM KCl. The disappearance of 9mer is unlikely to be due to an overall reduction in cleavage rates, because the reduction of cleavage rate is signi®cantly higher for 9mer production compared with 18mer production (Fig. 1) . This ®nding therefore supports a protein sliding model, by which HIV-RT generates preferential cleavages at 18mer and 9mer positions. We found that adding a cap structure to the 5¢ end of the RNA molecule generated a substrate, CGK1, which showed signi®cantly different signature cleavages for HIV RNase H compared with E.coli RNase HI. The RNA cleavage preference of HIV RNase H as well as the cleavage rates were identical on 5¢-phosphorylated and 5¢-capped substrates. This may re¯ect an adaptation of HIV RNA to allow the complete digestion of 5¢-capped HIV RNA during reverse transcription, as has been suggested previously (33) . Interestingly, the cleavage site choice was not affected by the addition of a cap structure to the RNA substrate, although capping resulted in the presence of an additional nucleotide at the 5¢ end of the RNA. A previous study suggested that on RNase H substrates with recessed RNA 5¢ ends, the polymerase active site was located at the RNA 5¢ end, leading to preferential RNA cleavage at a position 18 nucleotides downstream (31, 32) . Further studies are required to map the position of the polymerase active site relative to the RNase H active site on capped RNA substrates. The difference in cleavage site preference and divalent metal ion preference between E.coli and HIV RNases H con®rmed the absence of E.coli RNase HI contamination in the preparation of HIV-RT and suggested a signi®cant difference in active site structure and substrate interaction. HIV RNase H activity was strongly activated by Mn 2+ compared with Mg 2+ , whereas E.coli RNase HI was only weakly active in 0.1 mM MnCl 2 . Both enzyme active sites have shown the presence of two Mn 2+ ions in the active site of crystal structures. Therefore, these results are consistent with a model in which binding of two metal ions to E.coli RNase HI is possible, but inhibitory (activation/attenuation model) (22) . In contrast, HIV RNase H is highly active under conditions where two Mn 2+ ions are likely to bind to the active site (13) .
HIV RNase H could be activated by a combination of Mg 2+ and Mn 2+ or by a combination of Mg 2+ and Co 2+ ions to levels higher than that observed with each metal ion separately. In addition, the titration of Mg 2+ -bound enzyme with increasing concentrations of either Mn 2+ or Co 2+ generated bell-shaped dose±response curves, indicating a two-step titration process. The impact on activity by Co 2+ was lower than that achieved with Mn 2+ , which was similar to results obtained with in¯uenza endonuclease and could be related to increased loss of Co 2+ due to the formation of insoluble hydroxide (9) . The RNase H activities at the highest concentrations of Mn 2+ and Co 2+ were unchanged when measured in the presence or absence of Mg 2+ . This indicated the complete replacement of Mg 2+ in a biphasic process, consistent with a two-metal ion mechanism of RNA cleavage.
Compounds forming the N-hydroxyimide series of RNase inhibitors were established as probes for the interaction of two metal ions presented at a distance of 4±5 A Ê with three oxygen atoms. The N-hydroxyl group could function as a bridging ligand for both metal ions, with each metal ion undergoing an additional interaction with two carboxyl groups on the molecule. NMR studies with the isolated HIV RNase H domain con®rmed the interaction of N-hydroxyimide 1 with the protein, which occurred in the presence, but not in the absence of Mg 2+ (G.Williams, unpublished results). In addition, compounds which were inactive as RNase H inhibitors did not interact with the isolated HIV RNase H domain. Compound interaction with the protein in the presence of Mg 2+ caused a spectral change consistent with enol formation.
This could explain the fact that compounds 5 and 6 were inactive, as they have lost the ability to form the enol tautomer. N-Hydroxyimides were found to potently inhibit HIV RNase H, but not E.coli RNase HI activity. To our knowledge, this is the ®rst demonstration of an inhibitor that could differentially inhibit HIV, but not E.coli RNase HI. In addition, the active compounds also inhibited RNase H activity of the isolated HIV RNase H domain with similar potency, consistent with binding to the RNase H active site (J.Q.Hang, S.Rajendran, Y.Yang, Y.Li, P.Wong Kai In, H.Overton, K.E.B.Parkes, N.Cammack, J.A.Martin and K.Klumpp, submitted). Inhibition of in¯uenza virus RNA endonuclease was reported previously (11) . However, the potency of compound 1 was~15-fold lower with in¯uenza endonuclease compared with HIV RNase H. This could re¯ect the higher af®nity of in¯uenza endonuclease for substrate RNA compared with HIV-RT, because compound 1 competes with substrate binding to the active site (11) .
In¯uenza RNA polymerase and T7 RNA polymerase activities were not affected by compound 1, although measurable inhibition was observed with HIV DNA polymerase. There is signi®cant evidence suggesting that polymerase active sites contain only a single high af®nity metal ion-binding site, even though they catalyse nucleotide incorporation via a two-metal ion mechanism. The second metal ion is most probably carried into the active site as a complex with the nucleotide triphosphate substrate (35±37). Therefore, the results of enzyme inhibition are consistent with N-hydroxyimides showing signi®cant selectivity towards preformed two-metal ion compared with one-metal ion-binding sites. Preliminary structure±activity relationship (SAR) suggested the potential to increase potency and selectivity of these compounds by substitutions on the phenyl moiety.
Taken together, the results from single and multiple divalent metal ion titration and the successful design of twometal ion-selective enzyme inhibitors have provided strong evidence to suggest that the essential polymerase-independent HIV RNase H activity is provided by a two-metal ion active site structure. There was no indication of metal ion cooperativity for E.coli RNase HI, suggesting that a different mechanism of RNA cleavage may operate in the two closely related enzymes. The current data do not exclude the possibility that substrate structure or sequence may in¯uence the binding of metal ions, resulting in different active site structures catalysing functionally different RNase H activities. Also it is not known if the binding of metal ions to the polymerase active site may affect the RNase H activity of HIV-RT. Therefore, further experiments are aimed at the role of divalent metal ions in the polymerase-dependent, as well as the fast, primary cleavage reactions by HIV RNase H.
